XDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects ...

Continuing to advance the pipeline and remain on-track to engage with the FDA on TP-04 (Papulopustular Rosacea) and TP-05 ...

Although both blepharitis and styes affect the eyelids, the two conditions have different symptoms, causes, and treatment options. To help prevent developing a stye or blepharitis, a person can ...

Pleurisy, which is inflammation in the lining of your lungs (pleura) that causes pain when you breathe, doesn't always need treatment. But you should always see a doctor if you have chest pain ...

Blepharitis is not usually serious, but without treatment, it can escalate to dry eyes, cysts, or conjunctivitis. This health update came only a year after Bradley had a significant lifestyle ...

You’ve probably given someone the silent treatment once or twice (or maybe even more than that). You know the drill — you and your partner get into a heated argument that ends with hurt feelings and ...

Blepharitis can affect anyone, including people who do not have eczema. Eczema is characterized by flare-ups, which last for weeks or months, and remissions. Your healthcare provider will design a ...

The goal in treating ulcerative colitis is to reduce the inflammation, hopefully leading to remission. The two leading treatment options are medication and surgery. Approximately 70 percent of ...

No treatment option is perfectly effective for everyone, Dr. Yu said, but since medications were first developed for the condition decades ago, “we’ve come a long way.” Katie Mogg is a ...

However, severe hemorrhoids may require medical treatment. Hemorrhoids (sometimes called piles) are swollen veins in your anus and rectum that can cause pain, itching, and rectal bleeding.

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...